Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GAMEXP

Financiado

Cerrado

Genomic approaches to metabolite exploitation from Xenorhabdus Photorhabdus

The majority of compounds used to treat diseases come from a single group of organisms, the actinomycetes. This over-reliance on a single organism to produce the worlds drugs is a major problem for the development of compounds wit... ver más

31/08/2012

GUF

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-08-31 No tenemos la información de la convocatoria

0% 79% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

GUF

0.00€ | Lider

UBAH

N.D. | Participante

EURICE EUROPEAN RESEARCH AND...

N.D. | Participante

MAHIDOL UNIVERSITY

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PROSECMET Function and production of secondary metabolites 2M€ Cerrado

STEPN-UP Stilbene and entomopathogenic nematodes Unlocking the poten... 176K€ Cerrado

COGNISEPLANCTOMYCES Construction of a Genetic System for Planctomycetes 238K€ Cerrado

IDRAM The role of amphidial drug uptake in the mode of action and... 195K€ Cerrado

NAfrAM Novel antibiotics from Antarctic microbes 190K€ Cerrado

GoMyTri Golden Mycological Triangle joining forces to exploit myco... 333K€ Cerrado

Líder del proyecto

JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The majority of compounds used to treat diseases come from a single group of organisms, the actinomycetes. This over-reliance on a single organism to produce the worlds drugs is a major problem for the development of compounds with alternative modes of action which can overcome and delay the onset of drug resistance. To address this problem we will form an international multi-disciplinary group of experts to bioprospect for biologically active natural products. The central aim of this programme is to start rapidly deriving novel drugs from non-actinomycete sources. We will isolate novel strains of the proven but not well-explored drug producers Xenorhabdus and Photorhabdus. These bacteria will be isolated from insect pathogenic nematodes and characterized taxonomically (WP1) and strains will be analyzed for the production of novel compounds (WP2). This library of compounds will then be tested against a broad set of targets including bacteria, fungi, protozoans, nematodes, insects, and mammalian cell cultures (WP3). The five most productive bacterial strains will then be fully sequenced and used to construct genomic libraries. These libraries will be used to generate recombinant clones in heterologous hosts, enabling fast and efficient biotechnological production of the bioactive compounds (WP4). To ensure efficient interactions and comparability of results, especially regarding the bioactivity data, training sessions will be organized with seminars and hands on experience for each of the groups at a central site (WP5). Robust patent stuctures will ensure efficient technology transfer to our industrial partners (WP6) and overall coordination of the scientific and training programs will be overseen by WP7.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores